# Perioperative dexmedetomidine effects on delirium in elderly patients after noncardiac surgery: A retrospective propensity score analysis

**Authors:** Hong-Wei Wang, Qin-Jun Chu, Ze-Fei Zhu, Ming Cheng, Ze-Ping Li, Liang Zang, Long He, Lin-Na Chen, Qian He, Jian-Jun Yang, Han-Wen Gu

PMC · DOI: 10.3389/fphar.2025.1578233 · Frontiers in Pharmacology · 2025-05-23

## TL;DR

This study finds that using dexmedetomidine during surgery may reduce delirium in elderly patients.

## Contribution

The study provides evidence that perioperative dexmedetomidine reduces postoperative delirium in elderly noncardiac surgery patients.

## Key findings

- Dexmedetomidine reduced delirium incidence from 17.8% to 8.68% in elderly patients.
- The test group had lower pain scores and fewer tachycardia cases.
- Hypotension was more common in the dexmedetomidine group.

## Abstract

Delirium is a complex syndrome with limited pharmacological treatment options, whereas non-pharmacological prevention strategies warrant further investigation. Dexmedetomidine, an α2-adrenergic receptor agonist commonly used for sedation and analgesia, has shown potential anti-inflammatory effects that may contribute to delirium prevention. We conducted a retrospective PSM analysis to evaluate the effectiveness of dexmedetomidine in preventing postoperative delirium in elderly ICU patients undergoing noncardiac surgery.

A retrospective analysis was conducted, including patients undergoing noncardiac surgeries after surgery. The main outcome was the 7-day incidence of delirium. Secondary outcomes included the length of hospital stay, postoperative nausea and vomiting, and postoperative complications. Propensity score matching and regression models were utilized to adjust for confounders and to investigate associations between the use of dexmedetomidine and outcomes.

A total of 19,899 patients were included, and 3,169 pairs were matched after propensity score matching. After matching, the incidence of postoperative delirium was 8.68% in the cohort with perioperative dexmedetomidine (test group) and 17.80% in the cohort without dexmedetomidine (control group), p < 0.001. The numerical rating scale in the test group was significantly decreased (mean ± SD, 2.4 ± 0.9 vs. 2.6 ± 0.8, p < 0.001). Hypotension (14.86% vs. 14.04%, p < 0.001) was increased, whereas hypertension (10.67% vs. 13.13%, p < 0.001) and tachycardia (16.81% vs. 10.71%, p < 0.001) were decreased in the test group.

Perioperative infusion of dexmedetomidine may reduce the incidence of delirium in elderly patients after noncardiac surgery.

## Linked entities

- **Chemicals:** dexmedetomidine (PubChem CID 5311068)
- **Diseases:** delirium (MONDO:0045057)

## Full-text entities

- **Diseases:** Delirium (MESH:D003693), postoperative delirium (MESH:D000071257), Hypotension (MESH:D007022), postoperative nausea and vomiting (MESH:D020250), hypertension (MESH:D006973), inflammatory (MESH:D007249), tachycardia (MESH:D013610)
- **Chemicals:** Dexmedetomidine (MESH:D020927)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12141013/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12141013/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12141013/full.md

---
Source: https://tomesphere.com/paper/PMC12141013